Selecta Biosciences Inc (SELB) Reaches New 1-Year Low at $10.53
Selecta Biosciences Inc (NASDAQ:SELB)’s share price hit a new 52-week low during trading on Thursday . The stock traded as low as $10.53 and last traded at $10.59, with a volume of 21,958 shares trading hands. The stock had previously closed at $11.57.
Several brokerages have commented on SELB. Stifel Nicolaus started coverage on Selecta Biosciences in a report on Monday, July 18th. They set a “buy” rating and a $23.00 price target on the stock. Needham & Company LLC started coverage on Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $28.00 price objective for the company. Finally, Canaccord Genuity started coverage on Selecta Biosciences in a research report on Monday, July 18th. They issued a “buy” rating and a $20.00 price objective for the company.
The firm’s 50 day moving average is $13.72 and its 200-day moving average is $13.72.
In other news, major shareholder Nanodimension Management Ltd bought 385,000 shares of the business’s stock in a transaction on Monday, June 27th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $5,390,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Amir Nashat bought 150,000 shares of the business’s stock in a transaction on Monday, June 27th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $2,100,000.00. The disclosure for this purchase can be found here.
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.